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Effect of epilepsy on autism symptoms in
Angelman syndrome
Kristin A. Bakke1*, Patricia Howlin2,3, Lars Retterstøl4, Øivind J. Kanavin5, Arvid Heiberg4 and Terje Nærland1,6
Abstract
Background: Autism spectrum disorder and epilepsy often co-occur; however, the extent to which the association
between autism symptoms and epilepsy is due to shared aetiology or to the direct effects of seizures is a topic of
ongoing debate. Angelman syndrome (AS) is presented as a suitable disease model to explore this association.
Methods: Data from medical records and questionnaires were used to examine the association between age of
epilepsy onset, autism symptoms, genetic aberration and communication level. Forty-eight participants had genetically
verified AS (median age 14.5 years; range 1–57 years). A measure of autism symptoms (the Social Communication
Questionnaire; SCQ) was completed for 38 individuals aged ≥ 4 years. Genetic cause was subgrouped into deletion
and other genetic aberrations of the 15q11-q13 area. The number of signs used to communicate (< 20 sign and ≥ 20
signs) was used as a measure of nonverbal communication.
Results: Mean age of epilepsy onset was 3.0 years (range 3 months–7.8 years). Mean SCQ score for individuals without
epilepsy was 13.6 (SD = 6.7) and with epilepsy 17.0 (SD = 5.6; p = 0.17); 58% used fewer than 20 signs to communicate.
There were no age differences between groups according to presence of epilepsy, level of nonverbal communication
or type of genetic aberration. SCQ scores were higher in individuals with the deletion than in those with other genetic
aberrations (18.7 vs 10.8 p = 0.008) and higher in the group who used < 20 signs to communicate (19.4 vs 14.1 p = 0.007).
Age of epilepsy onset was correlated with SCQ (r = − 0.61, p < 0.001). Multiple regression showed that age of seizure
onset was significantly related to SCQ score (β = − 0.90; p = 0.006), even when the type of genetic abnormality was
controlled (R2 = 0.53; F = 10.7; p = 0.001).
Conclusions: The study provides support for the notion that seizures themselves contribute more to autism symptoms
than expected from the underlying genetic pathology alone. The study demonstrates how a rare genetic syndrome such
as Angelman syndrome may be used to study the relation between epilepsy and autism symptomatology.
Keywords: Angelman syndrome, Autism spectrum disorder, Epilepsy, Epileptic encephalopathy, Seizure onset
Background
Angelman syndrome (AS) is a neurodevelopmental dis-
order caused by an absent or non-functioning maternal
allele of chromosome 15q11-q13 [1]. The typical AS
phenotype is characterized by intellectual disability (ID),
lack of speech, hyperactivity, ataxic gait, microcephaly,
sleep disturbances, frequent laughter/smiling and an
apparently happy demeanour [1–4]. ID ranges from
moderate to profound, with most individuals functioning
in the severe to profound range [5, 6]. Epilepsy occurs in
80% or more of cases [2, 7], usually involving multiple
seizure types and starting in early childhood [7, 8]. High
rates of autistic symptoms are also reported [9–11], with
prevalence estimates of autism spectrum disorder (ASD)
ranging from 24 to 81% [6, 10]. AS can be due to
UBE3A mutations, uniparental disomy and imprinting
defects [1, 12], but deletions are the predominant cause
and are found in 68–75% of patients. Deletions are also
associated with more severe AS-phenotype, and co-
deletion of GABAA-receptor genes (GABRB3, GABRA5
and GABRG3) located adjacent to UBE3A gene is sug-
gested as a possible explanation for this [1]. Dysfunction
of GABRB3 is highly associated with both epilepsy and
autism symptoms [13, 14].
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A strong association between autism symptoms, epilepsy
and ID has been found in a number of other genetic syn-
dromes, such as fragile X and tuberous sclerosis complex
(TSC), as well as in AS [6, 10]. It is evident, too, that the
negative effect of seizures is particularly strong during
infancy and early childhood [15–18]. Thus, onset of
seizures during the first year of life is associated with
increased prevalence and severity of ID and ASD and
increased prevalence of brain abnormalities [19, 20].
However, there is a continuing debate [21–24] as to
whether autism symptoms, epilepsy and ID are inde-
pendent comorbidities [15, 16, 21, 25–27], whether they
are all outcomes of the same underlying pathophysio-
logical/genetic mechanisms [17, 21, 25, 28], or whether
the epilepsy itself contributes to more severe cognitive
and behavioural impairments than might be expected
from the underlying pathology alone [15, 17, 29, 30],
i.e. a so-called encephalopathic effect [30].
There are several reasons why AS offers a suitable disease
model to investigate the association between epilepsy, ID
and autism symptoms. Firstly, the rate of epilepsy in AS
(> 80%) is as high as or higher than other genetic disorders
in which epilepsy and autism commonly co-occur (e.g. TSC
[80–90%]; fragile X syndrome [10–20%]) [29, 31, 32]. Sec-
ondly, epilepsy in AS tends to start in very early childhood.
Seizures are also often treatment-resistant and refractory
epilepsy has been shown to be an important predictor of
autism symptoms [33]. Thirdly, unlike genetic conditions
such as TSC, in which the numbers and location of tubers
are associated with autism symptoms [17, 34], there are no
specific structural brain abnormalities in AS that are known
to affect the phenotype. Fourthly, knowledge of the specific
genetic defects that cause AS makes it possible to evaluate
the degree to which the association between epilepsy and
autism symptoms is a result of the underlying genetic
abnormality and to assess the independent contribution of
seizures on level of autism symptoms.
The aims of the current study were to describe epilepsy
characteristics and then investigate the relationship
between epilepsy, autism symptoms, communication level
and genetic cause in individuals with AS. Based on previ-
ous research on other populations with childhood epilepsy
including TSC [18, 33, 35–37], we hypothesized that age of
onset of epilepsy would be related to the number of autism
symptoms in AS independent of the effect of the specific
genetic abnormality.
Methods
The study was approved by the regional ethics committee
in Norway (REK 2014/1880).
Recruitment procedures
From the records of the Frambu Resource Centre for
Rare Disorders in Norway and the Norwegian Angelman
Association, 115 individuals with AS were identified. Letters
were sent to the parents/guardians of these individuals, and
they were asked to complete two questionnaires: the Social
Communication Questionnaire (SCQ), which measures
autism symptoms [38], and a study-specific question-
naire assessing epilepsy, medication and developmental
parameters. Written informed consent was given by all
parents/guardians allowing the researchers access to
medical records from all hospitals in Norway (Fig. 1).
Measures
Clinical information on epilepsy and genetic abnormality
Participants’ medical records were used to collect infor-
mation regarding epilepsy and the nature of the genetic
abnormality. Information on age of epilepsy onset, type
of seizure and treatment with anti-epileptic drugs was
recorded when available. Medical records were not
comprehensive for all individuals, and formal seizure
classification was not always performed.
Genetic data were also variable. When information was
available, the genetic abnormality was dichotomised into
‘deletion’ or ‘other’ (i.e. uniparental disomy, imprinting
defects and point mutations).
Autism symptoms
The lifetime version of SCQ was used to assess the number
of autism symptoms [38]. The SCQ contains 40 items
scored 0 or 1 and was designed to screen for a possible
diagnosis of autism in individuals aged 4 years and older
and with a mental age above 2 years [38]. It has also
frequently been used to measure autistic-type symptoms in
individuals with genetic syndromes including those with
AS [9, 11]. We did not classify participants as meeting/not
meeting the suggested cut-off scores for autism or ASD
(≥ 22 and ≥ 15, respectively [38]) since the validity of
these criteria has not been established for individuals
with genetic disorders associated with severe ID. Never-
theless, SCQ has often been used as the screening tool
in samples with low IQ [39, 40].
Communication level
Information about level of development was particularly
variable and often very limited. Although many parents
reported that they had previously been told their child
had severe to profound intellectual disability (in 7 cases,
the description was of ‘moderate’ disability), formal test
results were rarely recorded, and hence, the validity of
these categories was unknown. Although there were no
adequate data on IQ/developmental level, we did have
data on communication level. Signing was the major
mean of communication for most of the participants;
the majority had no use of words and no one used more
than 20 words. Categorical ratings of ‘use of signs’ (< 20
and 20–100 and > 100) were used to divide individuals
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into two groups; those using fewer than 20 signs to com-
municate and those with more than 20 signs.
Participants
Inclusion criteria
For the descriptive part of the study (‘Epilepsy characteris-
tics’), individuals were included if their parents/guardians
gave their consent to participation/access to medical
records and if their son/daughter had a genetically verified
diagnosis of AS. For the second part of the study (‘Relation
between epilepsy and autism symptoms, nonverbal com-
munication level and genetic aberration’), individuals were
required to be at least 4 years of age (i.e. minimum age for
the SCQ).
Parents/guardians of 56 out of the 115 individuals
identified from the records (49%) consented to par-
ticipate; 48 of these individuals (age range 1–57 years;
median 14 years 6 months) had a genetically verified
AS diagnosis. At the time of questionnaire comple-
tion (see Fig. 1), medical records confirmed that 34 in-
dividuals had epilepsy and 11 individuals did not. Three
boys (aged 1, 1, and 4 years, respectively) subsequently de-
veloped seizures; hence, the 4-year-old was included in
the no-epilepsy group in the part 2 of the study. SCQ
questionnaires were completed for 38 of 40 individuals
aged 4 years or older (SCQ was not completed for two
participants aged 57 and 40 years). See Table 1 for partici-
pants’ characteristics.
Statistical analysis
Associations between quantitative measures were ana-
lyzed by parametric statistics in SPSS (t test, Pearson’s
r). Due to small sample size, Mann-Whitney U test
was used when comparing SCQ in subgroups with/
without epilepsy and when comparing SCQ and age
of epilepsy onset in subgroups with/without deletion.
Fisher’s exact test was used for categorical data. Due
to small and unequal sample sizes, Hedges’ g was
used for effect sizes. Normality of residuals was checked
using visual inspection of P-P plots. Multiple regression
analysis was conducted to assess the impact of ‘age at
epilepsy onset’and ‘type of genetic aberration’ on SCQ
scores. Due to the combination of dichotomous and
continuous covariates, we report the standardized coef-
ficients (β). To correct for multiple comparisons, a sig-
nificance level of p ≤ 0.01 was chosen; Bonferroni ‘rule
of thumb’ was used to determine appropriate p level
(p = 0.05/5 = 0.01).
Fig. 1 Recruitment
Table 1 Characteristics of participants with Angelman
syndrome in parts 1 and 2 of study
Age Gender Genetics
Part 1:
Epilepsy
characteristics
(n=48)
Range: 1–57 years
Mean: 17.1 years
Median: 14.5 years
Male: 30
Female: 18
Deletion: 26 (16 males)
UPD: 4 (2 males)
Imprinting: 3 (1 male)
Mutation: 2 (1 male)
Unknown: 13 (10 males)
Part 2:
Relation between
epilepsy and autism
symptoms, nonverbal
communication
level and genetic
aberration (n=40)
Range: 1–57 years
Mean: 20.2 years
Median: 19.1 years
Male: 30
Female: 15
Deletion: 26 (16 males)
UPD: 2 (2 males)
Imprinting: 2 (1 male)
Mutation: 2 (1 male)
Unknown: 12 (9 males)
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Results
Part 1: epilepsy characteristics
Age of first seizure ranged from 3 months to 7 years
10 months (mean 3 years 0 months, SD 2 years 2 months).
Four individuals had their initial seizure during the first year
of life; 11 developed epilepsy during the second year. The
number and type of seizures varied among individuals and
varied over time in the same individuals. Two individuals
(aged 38 and 27 years) had been diagnosed with Lennox-
Gastaut syndrome. One individual had only ‘atypical
absence seizures’, and all others had seizures with ‘jerks’ or
‘convulsions’. More than one seizure type was recorded in
33 individuals. Seizures resembling generalized tonic-clonic
seizures (sometimes described as generalized convulsions)
were reported in 29 individuals. Seizures resembling
atypical absence seizures were seen in 17 individuals,
myoclonic seizures in 10 and atonic seizures in 13.
Focal seizures were seen in four individuals. Sixteen
individuals had their first seizure during a febrile episode,
and 10 participants were reported to have epileptic seizures
that were aggravated by fever. EEGs were recorded
repeatedly in several participants, and findings were
typical of those reported in AS [2]. When EEGs were
recorded prior to first seizure, delta waves but no
epileptiform activity were often reported. More epilepti-
form discharges in EEGs were recorded during periods of
seizure aggravation. Seizures were commonly reported to
be resistant to anti-epileptic drugs and drug resistance
was particularly marked before 6 years of age, and 21 indi-
viduals had received benzodiazepine as emergency treat-
ment. Three individuals had been treated with only one
anti-epileptic drug, and all others had tried two or more
anti-epileptic drugs. Valproate was the most frequently
prescribed anti-epileptic drug (31 participants), followed
by nitrazepam (18) and clonazepam (16).
Part 2: the relation between epilepsy and autism symptoms,
nonverbal communication level and genetic aberration
Mean SCQ was 16.3 (SD = 5.9 range: 0–27). SCQ scores
were higher in individuals with epilepsy (n = 31) than in
those without (n = 7), but the difference was not significant
(see Table 2). SCQ and age were not correlated (p = 0.12).
Level of nonverbal communication did not differ between
individuals with and without epilepsy; 19 of 33 (58%) with
epilepsy and 4 of 7 (57%) (exact p = 1.000) without epilepsy
used fewer than 20 signs to communicate. Individuals with
the deletion were more likely to be in the group using < 20
signs to communicate than individuals with other genetic
aberrations (exact p = 0.022).
Within the epilepsy group, age of epilepsy onset was
lower among individuals using < 20 signs to communicate.
Individuals with the deletion had significantly higher SCQ
scores and lower age at epilepsy onset than individuals
with other genetic aberrations. There were no differences
in age between groups (see Table 2 for details).
Age at epilepsy onset was highly correlated with SCQ
score (r = − 0.61, p = 0.0004). A linear regression was
conducted with SCQ as the dependent variable and age
at seizure onset and type of genetic abnormality as the
covariates (forced entry). Age at onset of seizures had an
independent contribution when entering the type of
genetic aberration as a covariate. The type of genetic
aberration did not have an independent contribution in
this model (see Table 3 and Fig. 2). As a supplementary
analysis, we included level of nonverbal communication
as a third covariate. Age of epilepsy onset was significant
also in this model (β = − 0.81, p = 0.007).
Discussion
This study explored the relationship between age of
epilepsy onset, autism symptomatology, type of genetic
aberration and nonverbal communication level in a
Norwegian sample of individuals with AS. Among the
56 individuals with AS identified from the available
databases, 48 (86%) had genetically verified AS. This is
in line with other reports noting that no genetic abnor-
mality can be identified in 10–15% of individuals with
AS [4]. Other clinical findings were similar to those of
previous studies of AS. Thus, deletions were the most
common genetic cause identified [1, 4]. With regard to
epilepsy, the prevalence in this study was 77%, some-
what lower than the rates of ≥ 80% commonly reported
[4, 7, 8, 41]. However, our sample included several very
young participants who may not yet have had their first
seizure. We also excluded individuals in whom the
cause of AS was unknown and there is some indication
Table 2 SCQ scores and age at onset of epilepsy according to communication level and genetic aberration
Epilepsy
(N = 31)
No epilepsy
(N = 7)
Epilepsy and level of nonverbal
communication (n = 31)
Epilepsy and type of genetic
aberration (n = 23)
p value
[Hedges’ g]
< 20 signs
(n = 17)
≥ 20 signs
(n = 14)
p value
[Hedges’ g]
Deletion
(n = 18)
Other genetic
aberration (n = 5)
p value
[Hedges’ g]
SCQ mean (SD) 17.0 (5.6) 13.6 (6.7) 0.354 [0.59] 19.4 (4.4) 14.1 (5.7) 0.007 [1.05] 18.7 (5.0) 10.8 (6.6) 0.007 [1.48]
Age at onset of
epilepsy mean (SD)
36.6 months
(26.0)
na na 30.2 months
(18.5)
44.4 months
(32.1)
0.160 [0.56] 25.2 months
(13.7)
79.0 months
(19.3)
< 0.001 [3.60]
Age (SD) 20.0 years (9.7) 13.0 years (9.6) 0.170 [0.72] 21.4 years (10.6) 18.2 years (8.6) 0.57 [0.33] 16.6 years (5.2) 17.4 years (9.5) 0.104 [0.13]
SCQ Social Communication Questionnaire score, na not applicable
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that individuals with AS of unknown cause may have the
highest prevalence of seizures [7]. Epilepsy characteristics
with early-onset epilepsy, multiple seizure types, a
tendency to have seizures during febrile episodes and
commonly treatment-resistant seizures, particularly in
early childhood, are also in line with the findings reported
by others [2, 7, 8, 41, 42], and the use of anti-epileptic
drugs is comparable to other studies [7, 8, 41].
The main focus of the study was the association
between age of epilepsy onset and extent of autism
symptomatology when type of genetic abnormality was
controlled for. Our findings from this study of individuals
with AS provide support for the notion that seizures
themselves contribute more to autism symptoms than
might be expected from the underlying pathology alone
[15–17, 21]. As anticipated, individuals with a deletion of
15q11-q13 had substantially more autism symptoms than
individuals with other genetic aberrations (g = 1.48). How-
ever, when entered into a regression model with epilepsy
onset, genetic aberration made no significant contribution
to the number of autism symptoms reported. Although
the lack of an independent effect of type of genetic aberra-
tion is likely due to the low number of causes other than
deletion, it should be noted that the slope of the regres-
sion lines is similar for both genetic subgroups, thus
supporting the importance of age at seizure onset across
the sample. These findings from AS parallel evidence from
studies in other rare disorders such as TSC; although both
early seizures and encephalopathy are highly associated
with type of genetic abnormality, early seizures may con-
tribute to a worsening of developmental outcome [17, 43].
Similarly, from fragile X syndrome, research indicates that
males with the FMR1 premutation are more likely to have
ASD and ID if seizures occur in childhood [29, 44].
Although individuals with epilepsy had more autism
symptoms than those without epilepsy, and despite a
moderate to large effect size, this difference was not
significant [15]. This may be due to the rarity of non-
epilepsy cases among individuals with AS and hence the
very small size of the no-epilepsy group. However, the
findings also point towards the importance of viewing
epilepsy as a spectrum disorder rather than a dichotomy
[15]. Hence, the comorbidity between autism symptoms
and epilepsy may be related both to the underlying
pathology and to the effect of seizures. The high risk of
ASD in populations with early-onset epilepsy has been
used to support the encephalopathy hypothesis, i.e. that
seizures may cause ASD [16, 25]. Others have argued
against this because the relationship is bi-directional
and individuals with ASD are at increased risk of future
epilepsy and seizures may occur in adolescence or
Table 3 Statistical results of regression model with SCQ as
dependent outcome
Standardized
coefficients
Unstandardized coefficients
Covariate β p B Standard
error
95% confidence
interval
Model with two covariates
R2 = 0.53; F = 10, 7; p = 0.001
Age at epilepsy onset − 0.90 0.006 − 0.21 0.07 − 0.35/− 0.07
Genetic aberration − 0.22 0.45 − 3.24 4.23 − 12.01/5.61
Fig. 2 Scatterplot of age at onset of epilepsy and SCQ. Fit-lines are shown according to the type of genetic abnormality
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adulthood [21, 22, 45, 46]. This study highlights the
importance of considering the additive effects of the
underlying genetic aetiology and seizures contributing
to autism symptoms in AS, which may be relevant also
for other conditions [15, 29]. The encephalopathic effect
may be greater when seizures start early. Early-life seizures
may result in molecular changes which impact neural
network structure, and the hippocampal region may be of
particular importance. Molecular changes may also influ-
ence the expression of genes involved in autism symptoms
and genetic syndromes such as GABRB3, FMR1, TSC1
and TSC2 [16, 29]. Moreover, research suggests that
effects of seizures on GABAA-receptor expression are
age-dependent, a finding that further supports the notion
that early seizures are particularly harmful [16].
There was no difference in the level of nonverbal com-
munication between the epilepsy group and no–epilepsy
group. Age of first seizure however, was associated with
nonverbal communication (g = 0.56) and individuals with
the lowest level of nonverbal communication had earlier
seizure onset than those who used more signs to com-
municate. A number of other studies has found that
earlier age of seizure onset is associated with poorer
cognitive outcome [18, 33, 35–37, 47, 48]. Our study
did not include a measure of development, only a measure
of nonverbal communication. However, supplemental
analysis showed that age of epilepsy remained significant
also when nonverbal communication was entered as a
covariate. This suggests that the number of autism symp-
toms was not explained only by the level of nonverbal
communication.
Although the findings of this exploratory study have
potentially important implications for understanding the
complex links between autism symptoms and epilepsy,
there are a number of limitations that must be taken
into account in the interpretation of the data. Firstly, the
sample size was small and the age of participants was
very wide, ranging from infancy to adulthood. In addition,
we did not have data on the level of ID, only an estimate
of nonverbal communication was available. There were
also few individuals with a genetic cause other than the
15q11 deletion, and we lacked data on size of deletions.
Furthermore, information from medical records was often
incomplete and formal seizure classification, except for
tonic-clonic seizures, was rarely performed. Hence, some
individuals may have had more types and higher frequency
of seizures than reported (particularly those of short dur-
ation or less severe such as absences and myoclonic
seizures). Finally, there was no clinical assessment of
autism, and rather than a categorical distinction between
ASD/non-ASD, we focused on the frequency of autism
symptoms as measured by the SCQ. While this avoided
the problems of misdiagnosing ASD in a population with
severe developmental delay, it is well established that the
number of autism symptoms is highly related to severity
of ID [11]. Thus, high rates of autism symptoms were to
be expected in this sample of individuals with AS [9, 10].
The severity of ID in AS is the main limitation when using
this disorder as a disease model for studying the relation
between autism symptoms and epilepsy.
It is clear that information from a larger sample of
individuals with AS, with a larger range of genetic causes
other than deletions, and detailed information on devel-
opmental level is needed to increase confidence in the
current findings. More details of the genetic aberration,
such as size and exact break points of the deletions, are
also needed. Finally, further studies in this area should
investigate which autism symptoms are particularly
vulnerable to early seizures and which are less affected.
Such knowledge may be of relevance for better under-
standing of the biology of ASD.
Conclusions
This study provides support for the notion that, in indi-
viduals with AS, seizures themselves contribute more
to autism symptoms than expected from the underlying
genetic pathology. This study demonstrates how a rare
condition may illuminate core issues in research on
developmental disorders. Individuals with Angelman
syndrome show limited variation in genetic aetiology,
and the condition is therefore a suitable one in which
to investigate the relation between epilepsy and autism
symptoms.
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